Isembyld (apitegromab-mstn)

Where it stands

Isembyld (apitegromab-mstn), from Scholar Rock Inc, was approved by the US FDA on 2026-09-11 under BLA761463. The records classify it as a new biologic and describe it as injectable. The listed status is Approved.

In the EU, the records show that the application was withdrawn on 2026-08-13. The withdrawal is listed under Scholar Rock Netherlands B.V. The records show no CHMP opinion date, so no CHMP opinion is recorded for this product. The product is therefore approved in the US and has no EU authorisation on the evidence provided.

The records leave the therapeutic area and the approved indication blank. This analysis does not state what condition the product treats or who the target patients are. Those details need to be taken from the FDA approval documents and the US prescribing information.

Regulatory pathway and designations

In the US, the product went through a Biologics License Application (BLA761463). The records give it two designations: New biologic and Priority review. Priority review is an FDA designation for applications that, if approved, would offer a significant improvement in the safety or effectiveness of treating a serious condition. It shortens the FDA's target review timeline compared with standard review. The records do not give the submission date, the review goal date or the basis for the designation, so the actual review duration cannot be calculated here.

The nonproprietary name carries the suffix "-mstn". This is the usual four-letter suffix FDA attaches to biologic names to distinguish products. The records do not say anything further about the product's mechanism or class.

In the EU, the records show only the withdrawal of the application on 2026-08-13. They do not say at which stage of review the application stood, whether a CHMP opinion was ever adopted, or why the sponsor withdrew. The reasons should not be inferred. Any public explanation would have to come from the EMA withdrawal documentation or company statements, which are not in the records.

Safety and pharmacovigilance

The records contain no safety data. They include no adverse event information, warnings, boxed warning status, REMS requirement or post-marketing commitments, so none are described here.

As general context, a US BLA approval comes with FDA-approved labeling, and the sponsor takes on routine pharmacovigilance obligations such as adverse event reporting. FDA can also require post-marketing studies or risk management measures. Whether any of these apply to Isembyld cannot be determined from the records and should be checked in the approval letter and label.

What to watch

The first check is the FDA approval package: the label, the approval letter and any post-marketing requirements or commitments. These will show the indication, the dosing and administration, the safety section and any follow-up obligations. The records provide none of these.

For the EU, the open question is whether and when the sponsor will resubmit. The records give no information on any new EU filing plan, so none should be assumed. Teams tracking the EU position should follow EMA publications on the withdrawn application and any later company disclosures.

Commercial and access planning in the US depends on label details that the records do not include. The records also give no launch timing, pricing or sales figures, and none are assumed here.